Skin Affecting Patents (Class 514/18.6)
-
Publication number: 20130336882Abstract: The adhesive composition for soft tissues, the adhesive composition for wound dressing or the wound dressing agent composition of the present invention is an adhesive composition for soft tissues, an adhesive composition for wound dressing or a wound dressing agent composition, comprising a monomer (A), a polymer (B) and a polymerization initiator composition (C) containing an organoboron compound, and is characterized by having a viscosity of 0.4 to 75,000 cp within 30 seconds after mixing of the components (A), (B) and (C). The composition of the present invention not only has low toxicity, low harmfulness and high adhesive strength but also is excellent in workability during application and is capable of forming films of excellent properties.Type: ApplicationFiled: August 14, 2013Publication date: December 19, 2013Applicant: Mitsui Chemicals, Inc.Inventors: Noriaki ASADA, Shinya Aoki, Hiroshi Naruse, Shoichi Miyakoshi, Masami Arata
-
Publication number: 20130338067Abstract: The present invention provides fusion proteins comprising a mucin-domain polypeptide covalently linked to an active protein that has improved properties (e.g. pharmacokinetic and/or physicochemical properties) compared to the same active protein not linked to mucin-domain polypeptide, as well as methods for making and using the fusion proteins of the invention.Type: ApplicationFiled: June 6, 2013Publication date: December 19, 2013Inventors: JUAN ALVAREZ, JEAN CHAMOUN, HEATHER C. LOSEY
-
Patent number: 8609618Abstract: A topical composition for application to aging skin, comprising an effective amount of S-acyl glutathione derivative of formula (I) wherein R1 consists of an unsaturated or saturated C16 group and R2 is a hydrogen, aliphatic or aromatic acyl group; and a dermatologically acceptable carrier. Preferred compositions comprise about 1.0% to about 3.0% by weight of S-palmitoyl glutathione.Type: GrantFiled: March 25, 2011Date of Patent: December 17, 2013Assignee: N.V. Perricone LLCInventor: Nicholas V. Perricone
-
Publication number: 20130331331Abstract: The present invention relates to a compound having a structure selected from: Ac-Nle-Glu-His-D-Phe-Arg-Trp-NH2 (SEQ ID NO: 1); or Ac-Nle-Gln-His-D-Phe-Arg-Trp-NH2 (SEQ ID NO: 2) or a pharmaceutically acceptable salt thereof. The compound of the salt thereof are particularly useful for the repair or prevention of damage of cellular DNA of dermal (skin) cells following UV irradiation in a mammal.Type: ApplicationFiled: February 13, 2012Publication date: December 12, 2013Inventor: Philippe Wolgen
-
Patent number: 8603973Abstract: The present invention provides a recombinant fusion protein which stimulates the rejuvenation and reactivation of skin and epidermal cells for improving skin appearance, smoothing wrinkles and freckles, and whitening skin. Particularly, the present invention provides various types of products for improving skin, which contain recombinant fusion protein of human serum albumin (HSA) with cytokine peptides (EGF, FGF, KGF, HGH, HGF, PDGF, GCSF, interferon, IL-11 or IGF) by genetic engineering technology. The fusion protein can be used independently or in a combination or combination with yeast fermentation products, or with varied emulsifiers, thickeners, moisturizer, preservatives, yeasts and ferments.Type: GrantFiled: September 24, 2008Date of Patent: December 10, 2013Assignees: Tianjin Sinobiotech Ltd., Fortunerock, Inc. USAInventors: Yan Fu, Zailin Yu
-
Publication number: 20130323187Abstract: The present invention describes material and methods related to synthetic peptides which block the secretion of neurotransmitters and induce muscle relaxation, and use of said peptides as inhibitors of neurotransmitter secretion and muscle contraction, and as inducers of muscle relaxation.Type: ApplicationFiled: November 26, 2012Publication date: December 5, 2013Applicant: PARTNERSHIP & CORP. TECHNOLOGY TRANSFERInventors: Nicolas Fasel, Amal Kuendig
-
Publication number: 20130324458Abstract: The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such as FGF23) and (optionally) a modified Fc fragment. The Fc fragment can, for example, have decreased binding to Fc-gamma-receptor and increased serum half-life. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23) and a modified Fc fragment.Type: ApplicationFiled: May 29, 2013Publication date: December 5, 2013Inventors: David GLASS, Shou-Ih HU
-
Patent number: 8598122Abstract: The invention is in the field of molecular medicine. It provides antagonistic compounds for frizzled 1 and/or frizzled-2 receptors, which may be useful in molecular imaging of the wound healing process after myocardial infarction and in therapeutic intervention into wound healing after remodeling of the heart, thereby ameliorating the consequences of myocardial infarction. The invention provides a method for antagonizing frizzled-1 or frizzled-2 receptors, wherein the receptor is contacted with a composition comprising a linear fragment of Wnt3(a) or Wnt5a or a functional analogue thereof, which comprises at least one cysteine residue, one threonine residue, one aspartic acid residue and one glycine residue.Type: GrantFiled: February 18, 2010Date of Patent: December 3, 2013Assignees: Universiteit Maastricht, Academisch Ziekenhuis MaastrichtInventors: Wessel Matthijs Blankesteijn, Hilde Laeremans, Tilman Mathias Hackeng
-
Patent number: 8598124Abstract: The present invention relates to peptides derived from human HMG-CoA reductase of general formula (I): R1-(AA)n-X1-Gly-Lys-X2-(AA)p-R2, And of sequence SEQ ID No. 1 to SEQ ID No. 10. The present invention also relates to a cosmetic or pharmaceutical composition comprising at least one peptide of general formula (I), in a physiologically suitable medium. The present invention further relates to the use of this novel peptide as an active principle that activates human HMG-CoA reductase in a cosmetic composition intended to strengthen the barrier function of the skin and to stimulate epidermal differentiation. The invention further applies to a cosmetic treatment method intended to prevent and/or combat the external stresses and signs of cutaneous aging.Type: GrantFiled: December 23, 2009Date of Patent: December 3, 2013Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8597717Abstract: Techniques for the production of flow-oriented collagen gels using hydrodynamics to influence the assembly of collagen fibers. Highly concentrated monomeric solutions of collagen are subjected to shear and extensional flow as they are drawn onto a substrate to induce fibrillogenesis under a high Ph buffer. The produced gel captures the flow induced ordering of molecular collagen upon fibril formation. The depositing or the induction of fibrillogenosis occurs without the application of a magnetic field to the concentration of collagen. These highly oriented 3D scaffolds are capable inducing contact guidance and guiding mammalian cell growth. The collagen fibers mimic the construction of in vivo fibers with the characteristic D-periodicity and the integrin receptors on the fibroblasts respond to this organization. The industrial applications of three-dimensional collagen gels as a biomaterial are widespread from drug delivery to burn repair or tissue engineering system.Type: GrantFiled: November 8, 2012Date of Patent: December 3, 2013Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Gerald G. Fuller, John E. Kirkwood
-
Publication number: 20130316956Abstract: The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like.Type: ApplicationFiled: June 17, 2013Publication date: November 28, 2013Applicant: Trustees of Tufts CollegeInventor: IRA M. HERMAN
-
Publication number: 20130316955Abstract: The present invention relates to compounds of the formula (I) and in particular medicaments comprising at least one compound of the formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which cathepsin D is involved, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.Type: ApplicationFiled: January 9, 2012Publication date: November 28, 2013Applicant: MERCK PATENT GMBHInventors: Markus Klein, Christos Tsaklakidis, Hans Guehring, Brigitta Leuthner
-
Publication number: 20130316942Abstract: The present invention relates to potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties. Specifically, the present invention relates to short peptides having these properties, and to methods and uses of such short peptides in clinical and cosmetic applications.Type: ApplicationFiled: August 9, 2013Publication date: November 28, 2013Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
-
Patent number: 8586540Abstract: The present invention relates to a culture medium for the fetus-derived mesenchymal stem cells in amniotic fluid. More particularly, the present invention relates to a composition for improving skin conditions, comprising the culture medium of fetus-derived mesenchymal stem cells in amniotic fluid as an active ingredient, in which the skin conditions to be improved include whitening, wrinkles, skin damages caused by UV rays or skin lifting. Further, the present invention relates to a method for preparing the composition, comprising the steps of culturing the fetus-derived mesenchymal stem cells in amniotic fluid; and collecting the culture medium.Type: GrantFiled: March 19, 2010Date of Patent: November 19, 2013Assignee: Stemmedience Co., Ltd.Inventors: Seungkwon You, Byung Sun Yoon, Jai-Hee Moon, Eun Kyoung Jun, Jonggun Kim, Hye-Youn Jung, Jung Han Lee, Eulsoon Park, Isaac Maeng, Jun Sung Kim, Jang Ho Lee, Hwang Heui Lee, Jong Won Lee, Kyoung Shik Cho
-
Patent number: 8580920Abstract: The present invention relates to novel peptides and to topical and food compositions comprising them. The novel peptides have applications in skin lightening and immunomodulation when applied topically and to immunomodulation and modulation of body mass when consumed in food compositions.Type: GrantFiled: November 23, 2010Date of Patent: November 12, 2013Assignee: Conopco, Inc.Inventors: Ganesh Chandramowli, Babu Rakesh Kumar Bandi
-
Patent number: 8580741Abstract: The present invention relates to a skin-tightening cosmetic composition and a method of applying the same, and more specifically, to a cosmetic composition a method of applying the same that includes a hydrolyzed plant protein and glycoprotein. The cosmetic composition includes a hydrolyzed plant protein and glycoprotein in an optimal amount, thereby causing the occurrence of an immediate contraction effect and a long-lasting contracting effect, and achieving skin improvements such as skin moisturizing and induction of synthesizing collagen and elastine in use of the composition over a long period of time.Type: GrantFiled: January 11, 2007Date of Patent: November 12, 2013Assignee: STC Nara Co., Ltd.Inventors: Kye-Ho Lee, Sung-Ho Chung, Ji-Hoon Song, Jin-Sung Yoon, Ji-Hyun Lee, Moon-Ju Jung, Jong-Hwan Kim
-
Patent number: 8580742Abstract: Topical compositions to address menopausal skin conditions comprise an effective amount of S-acyl glutathione derivative and a carrier. Methods for addressing menopausal skin conditions comprise applying a composition containing S-acyl glutathione derivative in a dermatologically acceptable carrier to skin tissue. The acyl group is a saturated or unsaturated aliphatic C12-C24 group, preferably an unsaturated C16-C24 group, most preferably an unsaturated C18 group. In particularly preferred embodiments, the acyl group is a linoleoyl group.Type: GrantFiled: March 5, 2010Date of Patent: November 12, 2013Assignee: N.V. Perricone LLCInventor: Nicholas V. Perricone
-
Publication number: 20130296239Abstract: The invention relates to a material for wound healing and skin reconstruction containing a peptide, wherein the peptide is a self-assembling peptide which is an amphiphilic peptide having 8 to 200 amino acid residues with periodic repeats of alternating hydrophilic amino acids and hydrophobic amino acids, and forms a stable ?-sheet structure in an aqueous solution in the presence of a monovalent ion. The material for wound healing and skin reconstruction of the present invention is capable of healing a wound area of mammals quicker than spontaneous recovery without leaving any scars, wherein the material has no potential risk of infectious disease such as virus transmission.Type: ApplicationFiled: December 21, 2012Publication date: November 7, 2013Inventors: Kentaro Takamura, Jiro Takei
-
Patent number: 8575089Abstract: The present invention relates to a composition containing Substance P for preventing or treating an inflammation. The composition containing Substance P according to the present invention exhibits the effect of decreasing leukocytes, neutrophils and hematopoietic stem cells in a blood, which are associated with the inflammation, and of increasing anti-inflammatory cytokines, regulatory T-lymphocytes, anti-inflammatory macrophages and the like, thereby terminating inflammatory response at an early stage, and is thus highly effective in preventing and treating the inflammation caused by a non-traumatic, traumatic, infectious or ischemic retinal injury.Type: GrantFiled: August 17, 2010Date of Patent: November 5, 2013Assignee: University-Industry Cooperation Group of Kyung HeeInventors: Young Sook Son, Hyun Sook Hong, Do Yeon Kim, Eun Kyung Lee
-
Publication number: 20130288964Abstract: The current invention relates to the use of a peptide comprising an amino acid sequence in the preparation of a medicament for the regeneration of tissue, preferably for the treatment of a wound. Further the invention relates to compositions comprising such peptides, and use of said peptides in both medical and nonmedical (cosmetic) applications.Type: ApplicationFiled: March 14, 2013Publication date: October 31, 2013Inventors: Johannes Gerhardus Maria Bolscher, Arie van Nieuw Amerongen, Engelmundus Cornelis Ignatius Veerman, Menno Johannes Oudhoff, Willem van't Hof, Kamran Nazmi, Petronella Adriana Maria van den Keijbus
-
Patent number: 8569234Abstract: Described herein are compositions comprising an alpha-MSH analogue and a transdermal delivery system and methods for inducing melanogenesis and/or preventing UV radiation-induced skin damage in a subject by topical administration of these compositions.Type: GrantFiled: October 7, 2005Date of Patent: October 29, 2013Assignee: Clinuvel Pharmaceuticals LimitedInventors: Michael John Kleinig, Kenneth B. Kirby, Berno I. Pettersson, Jr.
-
Patent number: 8569243Abstract: The present invention relates to sirtuin 6 activating peptides derived from highly conserved regions of human Sirtuin (SIRT) proteins, and to a cosmetic or pharmaceutical composition comprising at least one sirtuin 6 activating peptide in a physiologically acceptable medium. The invention further relates to the utilization of a cosmetic composition to prevent and/or repair Deoxyribonucleic acid (DNA) degradation, improve telomere maintenance and reduce cellular senescence. The invention also applies to a cosmetic treatment process intended to prevent and/or treat the cutaneous signs of aging and photo aging.Type: GrantFiled: June 23, 2011Date of Patent: October 29, 2013Assignees: ISP Investments Inc., ELC Management LLCInventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto, Isabelle Imbert, Nadine Pernodet
-
Patent number: 8568748Abstract: The present invention relates to a pharmaceutical formulation in colloidal form for topical application for the therapy and prophylaxis of pathological changes of the skin and/or integumentary structures of the skin and/or mucous membranes, including mucous membranes of the digestive tract, uro-genital tract and bronchial system and/or conjunctiva, containing a lipophilic phase in a quantity of 1-10% by weight, a mixture of surfactant and co-surfactant in a quantity of 1-50% by weight, a hydrophilic phase in a quantity of 40-80% by weight and, as active ingredient, cyclosporin and/or derivatives thereof in a concentration of 0.1-20% by weight.Type: GrantFiled: December 14, 2001Date of Patent: October 29, 2013Assignee: JAGOTEC AGInventors: Johannes Wohlrab, Reinhard Neubert, Konstanze Jahn
-
Patent number: 8562984Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.Type: GrantFiled: July 18, 2011Date of Patent: October 22, 2013Assignee: ZymoGenetics, Inc.Inventors: Penny Thompson, Hal Blumberg, Yasmin A. Chandrasekher, Julia E. Novak
-
Patent number: 8563514Abstract: Provided is a pharmaceutical composition for sequestering cells in connective tissue. The composition includes a biocompatible scaffolding to which one or more peptides or proteins are linked. The peptides or proteins have an amino acid sequence that is a subsequence of human ficolin and are capable of binding the cells to be sequestered. The pharmaceutical composition can be used in the treatment of connective tissue, and can be used as a dermal filler.Type: GrantFiled: August 14, 2008Date of Patent: October 22, 2013Assignee: MetamorefixInventors: Mazal Dahan, Raphael Gorodetsky
-
Publication number: 20130274197Abstract: The present invention provides a family of benzodiazepinone compounds and pharmaceutical compositions thereof. The present invention also provides methods of treating certain skin conditions, e.g., atopic dermatitis, rosacea, or psoriasis, by administering a benzodiazepinone and methods of reducing the proliferation of keratinocyte cells by exposing such cells to a benzodiazepinone.Type: ApplicationFiled: June 5, 2013Publication date: October 17, 2013Inventor: Gary D. Glick
-
Patent number: 8557295Abstract: The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. In preferred embodiments, the methods and agents comprise active extracts produced from fish eggs. The invention further provides processes for making active fish egg extracts.Type: GrantFiled: May 5, 2011Date of Patent: October 15, 2013Assignee: Regenics ASInventors: Runhild Gammelsaeter, Jan Remmereit
-
Publication number: 20130267471Abstract: This invention relates to a topical gel drug product preparation containing a composition comprising an isolated polypeptide having a carboxy-terminal amino acid sequence of an alpha connexin (ACT peptide), peptide stabilizers, excipients, buffering agents, and the like. A formulation and preparation steps are disclosed for the manufacturing of a stable, elegant, and pourable topical gel. The resulting formulation possesses long term stability suitable for aesthetic as well as therapeutic applications including the prevention of scaring and accelerated healing of wounds. Methods for treatment of chronic wounds, including chronic ulcers, are also provided.Type: ApplicationFiled: March 15, 2013Publication date: October 10, 2013Inventors: Gautam Ghatnekar, Tuan Elstrom
-
Publication number: 20130267463Abstract: Provided are a pharmaceutical use of poly-gamma-glutamic acid used for preventing or treating Th17-mediated diseases, a composition for preventing or treating Th17-mediated diseases comprising poly-gamma-glutamic acid as an active ingredient, and a method of preventing or treating Th17-mediated diseases using the same. The pharmaceutical composition is effective in inhibiting the differentiation of Th17 cells while promoting Treg cells, and, thus, can be useful in preventing or treating Th17-mediated diseases such as multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, Crohn's disease, ankylosing spondylitis, and the like.Type: ApplicationFiled: November 15, 2012Publication date: October 10, 2013Applicant: Industry-University Cooperation Foundation Hanyang UniversityInventors: Jeehee YOUN, Tae-Hwan KIM, Kyuheon LEE
-
Patent number: 8546340Abstract: A soothing cosmetic or pharmaceutical composition that includes at least one peptide that activates human HMG-CoA reductase general formula (I): R1-(AA)n-X1-Gly-Glu-Leu-Ser-X2-X3-(AAp-R2 in a physiologically suitable medium is disclosed. The invention further applies to a cosmetic treatment method intended to combat skin irritations. Additionally, methods of treating skin irritations with such a composition are described.Type: GrantFiled: December 23, 2009Date of Patent: October 1, 2013Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8545851Abstract: The present invention relates to a composition for improving inflammatory disease, and more specifically to a composition for improving inflammatory disease able to improve inflammatory reactions and the barrier function of epithelial tissue such as the skin, to enhance aging resistance and skin elasticity and to prevent or treat aging.Type: GrantFiled: January 7, 2010Date of Patent: October 1, 2013Assignee: SNU R&DB FoundationInventors: Jang Hee Oh, Ji-Yong Jung, Dong Hun Lee, Serah Lee, Yeon Kyung Kim, Jeong-eun Shin, June Hyunkyung Lee, Jin Ho Chung
-
Publication number: 20130251651Abstract: The present invention provides methods and compositions designed for treating a subject suffering from skin conditions, disorders or diseases. The compositions include fetal skin cell proteins obtained from fetal skin cells after induced cell lysis.Type: ApplicationFiled: May 13, 2013Publication date: September 26, 2013Applicant: NEOGYN, INC.Inventors: Lee Laurent-Applegate, Patrick Hohlfeld
-
Publication number: 20130251660Abstract: Disclosed are skin wetting and penetrating compositions and methods, where the compositions comprise the following, or combinations thereof: a surfactant, yeast exo-proteins, a stabilizer, and optionally an oil, humectant, or dermatological active agent.Type: ApplicationFiled: March 26, 2013Publication date: September 26, 2013Applicant: ADVANCED BIOCATALYTICS CORP.Inventors: Michael G. GOLDFELD, Andrew H. MICHALOW, Carl W. PODELLA, John W. BALDRIDGE
-
Publication number: 20130251821Abstract: The present invention provides fusion proteins comprising an extracellular domain of a VEGF receptor and a death ligand. The fusion proteins bind to VEGF and to death receptors on tumor cells thereby inhibiting VEGF activation of VEGF receptors and inducing apoptosis in the tumor cells. Fusion proteins of the present invention are useful for inducing apoptosis and cytotoxic effects in cells, treating cancer and diseases or disorders related to unregulated angiogenesis and/or vasculogenesis. Thus, this invention further provides methods for treating angiogenesis related diseases using the fusion proteins, polynucleotides encoding the fusion proteins, vectors containing the polynucleotides, pharmaceutical compositions and kits containing the fusion proteins or the polynucleotides encoding the fusion proteins.Type: ApplicationFiled: October 18, 2012Publication date: September 26, 2013Applicant: The Regents of the University of CaliforniaInventor: TIMOTHY P. QUINN
-
Patent number: 8541361Abstract: The present invention relates to compositions comprising a peptide with 2-12 amino acids substituted with a lipophilic moiety and a water soluble salt of an alkali, earth alkaline metal or transition metal. Furthermore, the invention relates to a container comprising such compositions. Additionally, the invention relates to the use of a water soluble salt of an alkali, earth alkaline metal or transition metal for reducing the adhesion of a peptide with 2-12 amino acids substituted with a lipophilic moiety to a surface.Type: GrantFiled: April 23, 2010Date of Patent: September 24, 2013Assignee: DSM IP Assets B.V.Inventors: Marc Heidl, Roman Wille, Hugo Ziegler
-
Publication number: 20130243797Abstract: The invention discloses a composition comprising at least one N-acetyl lactosamine, at least one sialylated oligosaccharide and at least one fucosylated oligosaccharide, and a hydrolysate comprising partially and/or extensively hydrolysed proteins, for use in the prevention and/or treatment of skin conditions and skin diseases. Preferably said composition is a starter infant formula. Said skin disease is in particular atopic dermatitis.Type: ApplicationFiled: November 21, 2011Publication date: September 19, 2013Inventor: Norbert Sprenger
-
Publication number: 20130244948Abstract: The disclosure provides a composition that comprises co-culture of small embryonic-like stem cells and mesenchymal stem cells, where cell media is reduced or lacking in exogenously supplied growth factors, as well as compositions of growth media that result from, or are manufactured by, co-culture of at least two types of different cells. Also provided are methods for selecting cell media that meet criteria pertaining to cell migration (gap assays) and to confluence.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: Scharp Technologies, Inc.Inventor: David W. Scharp
-
Patent number: 8535904Abstract: A method for adjusting calcium ion in epidermis is described. The method involves applying a material for enhancing skin barrier function to the skin of a subject.Type: GrantFiled: May 21, 2012Date of Patent: September 17, 2013Assignee: Pola Chemical Industries Inc.Inventors: Shohei Kuroda, Takuya Yamamoto, Yuko Saeki, Masumi Kurasawa
-
Patent number: 8536135Abstract: The present invention is related to methods of generating adaptive biochemical signatures in live cells and the use of said signatures to identify diagnostic and therapeutic modalities for human disease. The methods described herein comprise contacting a provocative agent to live cells and measuring and analyzing adaptive readouts. The methods of the invention may be used for therapeutic or diagnostic purposes.Type: GrantFiled: February 25, 2011Date of Patent: September 17, 2013Assignee: Ontherix, Inc.Inventor: Desmond Mascarenhas
-
Patent number: 8529897Abstract: The various embodiments provide a composition that provides local control over inflammation. The composition localizes the activities of the cytokine-neutralizing antibodies to the site of inflammation through covalent attachment to hydrophilic matrices. The various embodiments including a hydrophilic polymer, a ligand binding moiety covalently attached to the polymer, and optionally, a cellular adhesion peptide covalently attached to the polymer. The hydrophilic polymer may be a glycosaminoglycan such as hyaluronan. The cellular adhesion peptide may be a linear RGD peptide sequence covalently attached to the polymer. The ligand binding moiety may be a monoclonal antibody covalently attached to the polymer. The antibody may be selected from the group consisting of an anti-IL-1?, an anti-IL-6, an anti-TNF-?, and combinations thereof. The polymer functions as a substrate or matrix for cell migration and tissue regeneration.Type: GrantFiled: August 15, 2008Date of Patent: September 10, 2013Assignee: Carnegie Mellon UniversityInventors: Newell Washburn, Sidi Ahmed Bencherif, Liang Tso Sun
-
Patent number: 8530406Abstract: The present invention relates to a peptide of general formula (I): R1-(AA)n-X1-Gly-Glu-Leu-Ser-X2-X3-(AA)p-R2, derived from human HMG-CoA reductase. The present invention also relates to a cosmetic or pharmaceutical composition comprising at least one peptide of general formula (I), in a physiologically suitable medium. The present invention further relates to the use of this novel peptide as an active principle that activates human HMG-CoA reductase in a cosmetic composition intended to strengthen the barrier function of the skin and to stimulate epidermal differentiation. The invention further applies to a cosmetic treatment method intended to prevent and/or combat the external stresses and signs of cutaneous aging.Type: GrantFiled: December 23, 2009Date of Patent: September 10, 2013Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20130231291Abstract: The present invention concerns a mixture comprising isoflavones-aglicones, such as daidzein, genistein and glycitein, in addition to equol and lunasin, said mixture being based on soya fermented using lactic acid bacteria isolated from food matrices and use of said mixture for protection of skin and similar and of human intestinal cells with particular reference to prevention of inflammatory state and protection of barrier functions and hair loss treatment.Type: ApplicationFiled: July 11, 2011Publication date: September 5, 2013Inventors: Giammaria Giuliani, Anna Benedusi, Marco Gobbetti, Raffaella Di Cagno, Sergio Baroni, Carlo Giuseppe Rizzello
-
Publication number: 20130225501Abstract: Skin quality is improved by orally administering a cystatin and/or a degraded product of cystatin in an amount of 10 ?g/day or more per adult, or applying a composition that includes a cystatin and/or a degraded product of cystatin in an amount of 0.001 to 2 wt % based on a total amount of the composition.Type: ApplicationFiled: September 29, 2011Publication date: August 29, 2013Applicant: MEGMILK SNOW BRAND CO., LTD.Inventors: Ken Kato, Aiko Ono, Hiroshi Ueno, Noriko Ueda, Hiroaki Matsuyama
-
Publication number: 20130225478Abstract: Peptides are provided that are capable of inhibiting cell activation mediated by a Toll-like receptor (TLR) selected from TLR 1, 2, 4 or 6, said peptide comprising a sequence consisting of, or found within, the sequence of the transmembrane domain of a TLR selected from TLR 1, 2, 4 or 6 and optionally cytoplasmic and extracellular regions flanking the transmembrane domain. These peptides as well as pharmaceutical composition comprising them are useful for the treatment of TLR-mediated disease.Type: ApplicationFiled: July 19, 2011Publication date: August 29, 2013Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Yechiel Shai, Avner Fink, Eliran-Moshe Reuven, Liraz Shmuel-Galia
-
Patent number: 8518878Abstract: It is to provide a method for treating skin aging, or a method for treating skin scar that can exert a sufficient effect. A composition for treating skin aging comprising bFGF for treating aging of the skin that is administered intradermally or subcutaneously, or a composition for treating skin scar comprising bFGF for treating scar of skin that is administered intradermally or subcutaneously is utilized. Preferred examples of aging of skin include skin wrinkle, pigmented spot, sagging skin, rough skin, skin thinning, decrease of skin viscoelasticity, etc., and preferred examples of scar include keloid, hypertrophic scar, scar contracture, etc.Type: GrantFiled: September 15, 2011Date of Patent: August 27, 2013Assignee: Labo Juversa Co., Ltd.Inventor: Ichiro Ono
-
Publication number: 20130216551Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: December 12, 2012Publication date: August 22, 2013Applicant: CELERA CORPORATIONInventor: CELERA CORPORATION
-
Publication number: 20130216539Abstract: The present invention includes methods of generating derivatives of a protein, as well as methods of treating a subject with the derivatized proteins. More particularly, the present invention includes methods of generating derivatives of HSP 70 proteins and methods of treating a subject with the derivatized HSP 70 proteins.Type: ApplicationFiled: February 15, 2013Publication date: August 22, 2013Applicant: ALS Biopharma, LLCInventor: ALS Biopharma, LLC
-
Patent number: 8513185Abstract: Peptides are provided consisting of L- and/or D-amino acids and combinations thereof, which affect myeloid cells by action on the triggering receptors expressed on myeloid cells (TREMs), including TREM-1 and TREM-2. The peptides act on the TREM/DAP-12 signaling complex. Also provided are lipid and sugar conjugated peptides comprising L- or D-amino acids. A method is provided of designing the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The disclosure relates to the therapy of various myeloid cell-related disease states involving the use of these peptides and compounds. The peptides and compounds are useful in the treatment and/or prevention of a disease or condition where myeloid cells are involved or recruited. The peptides of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).Type: GrantFiled: October 13, 2010Date of Patent: August 20, 2013Inventor: Alexander B. Sigalov
-
Publication number: 20130209486Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: October 22, 2012Publication date: August 15, 2013Applicant: CELERA CORPORATIONInventor: Celera Corporation
-
Publication number: 20130209463Abstract: This invention relates to a protein C1ORF32 and its variants and fragments and fusion proteins thereof, and methods of use thereof for immunotherapy, and drug development, including but not limited to as immune modulators and for immune therapy, including for autoimmune disorders.Type: ApplicationFiled: June 30, 2011Publication date: August 15, 2013Applicant: COMPUGEN LTD.Inventors: Galit Rotman, Iris Hecht, Zurit Levine, Joseph R. Podojil, Stephen D. Miller